The role of H2S bioavailability in endothelial dysfunction

Rui Wang; Csaba Szabo; Fumito Ichinose; Asif Ahmed; Matthew Whiteman; Andreas Papapetropoulos

doi:10.1016/j.tips.2015.05.007

The role of H₂S bioavailability in endothelial dysfunction

Rui Wang^*
, Csaba Szabo
, Fumito Ichinose
, Asif Ahmed
, Matthew Whiteman
, Andreas Papapetropoulos

^*Corresponding author for this work

Massachusetts General Hospital
University of Exeter
Université Laurentienne
University of Texas Medical Branch
Harvard University
National and Kapodistrian University of Athens
Evangelismos Hospital

Research output: Contribution to journal › Article › peer-review

160 Citations (Scopus)

Abstract

Endothelial dysfunction (EDF) reflects pathophysiologicalchanges in the phenotype and functions of endothelial cells that result fromand/or contribute to a plethora of cardiovascular diseases. We review the roleof hydrogen sulfide (H₂S) in the pathogenesis of EDF, one of thefastest advancing research topics. Conventionally treated as an environmentpollutant, H₂S is also produced in endothelial cells and participatesin the fine regulation of endothelial integrity and functions. Disturbed H₂Sbioavailability has been suggested to be a novel indicator of EDF progress andprognosis. EDF manifests in different forms in multiple pathologies, buttherapeutics aimed at remedying altered H₂S bioavailability maybenefit all.

Original language	English
Pages (from-to)	568-578
Number of pages	11
Journal	Trends in Pharmacological Sciences
Volume	36
Issue number	9
Early online date	9 Jun 2015
DOIs	https://doi.org/10.1016/j.tips.2015.05.007
Publication status	Published - 2015

Bibliographical note

Funding: Natural Sciences and Engineering Research Council of Canada (NSERC); American Diabetes Association, the US National Institutes of Health (NIH), and the Shriners Hospitals for Children; UK Medical Research Council (MRC); British Heart Foundation (RG/09/001/25940), MRC (G0700288), Royal Society, and the European Commission; Aristeia grant (1436) that is co-financed by the European Commission (ESF) and Greek national funds through the Operational Program ‘Education and Lifelong Learning’; and OST (Cooperation in Science and Technology) Action BM1005 (ENOG: European Network on Gasotransmitters

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

cystathionine gamma-lyase
endothelium-derived hyperpolarizing factor
gasotransmitters
heme oxygenase-1
hydrogen sulfide
nitric oxide

Access to Document

10.1016/j.tips.2015.05.007

Cite this

@article{255338cbd6cb4ecd8207124169ce9cb5,

title = "The role of H2S bioavailability in endothelial dysfunction",

abstract = "Endothelial dysfunction (EDF) reflects pathophysiologicalchanges in the phenotype and functions of endothelial cells that result fromand/or contribute to a plethora of cardiovascular diseases. We review the roleof hydrogen sulfide (H2S) in the pathogenesis of EDF, one of thefastest advancing research topics. Conventionally treated as an environmentpollutant, H2S is also produced in endothelial cells and participatesin the fine regulation of endothelial integrity and functions. Disturbed H2Sbioavailability has been suggested to be a novel indicator of EDF progress andprognosis. EDF manifests in different forms in multiple pathologies, buttherapeutics aimed at remedying altered H2S bioavailability maybenefit all.",

keywords = "cystathionine gamma-lyase, endothelium-derived hyperpolarizing factor, gasotransmitters, heme oxygenase-1, hydrogen sulfide, nitric oxide",

author = "Rui Wang and Csaba Szabo and Fumito Ichinose and Asif Ahmed and Matthew Whiteman and Andreas Papapetropoulos",

note = "Funding: Natural Sciences and Engineering Research Council of Canada (NSERC); American Diabetes Association, the US National Institutes of Health (NIH), and the Shriners Hospitals for Children; UK Medical Research Council (MRC); British Heart Foundation (RG/09/001/25940), MRC (G0700288), Royal Society, and the European Commission; Aristeia grant (1436) that is co-financed by the European Commission (ESF) and Greek national funds through the Operational Program {\textquoteleft}Education and Lifelong Learning{\textquoteright}; and OST (Cooperation in Science and Technology) Action BM1005 (ENOG: European Network on Gasotransmitters",

year = "2015",

doi = "10.1016/j.tips.2015.05.007",

language = "English",

volume = "36",

pages = "568--578",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier",

number = "9",

}

TY - JOUR

T1 - The role of H2S bioavailability in endothelial dysfunction

AU - Wang, Rui

AU - Szabo, Csaba

AU - Ichinose, Fumito

AU - Ahmed, Asif

AU - Whiteman, Matthew

AU - Papapetropoulos, Andreas

N1 - Funding: Natural Sciences and Engineering Research Council of Canada (NSERC); American Diabetes Association, the US National Institutes of Health (NIH), and the Shriners Hospitals for Children; UK Medical Research Council (MRC); British Heart Foundation (RG/09/001/25940), MRC (G0700288), Royal Society, and the European Commission; Aristeia grant (1436) that is co-financed by the European Commission (ESF) and Greek national funds through the Operational Program ‘Education and Lifelong Learning’; and OST (Cooperation in Science and Technology) Action BM1005 (ENOG: European Network on Gasotransmitters

PY - 2015

Y1 - 2015

N2 - Endothelial dysfunction (EDF) reflects pathophysiologicalchanges in the phenotype and functions of endothelial cells that result fromand/or contribute to a plethora of cardiovascular diseases. We review the roleof hydrogen sulfide (H2S) in the pathogenesis of EDF, one of thefastest advancing research topics. Conventionally treated as an environmentpollutant, H2S is also produced in endothelial cells and participatesin the fine regulation of endothelial integrity and functions. Disturbed H2Sbioavailability has been suggested to be a novel indicator of EDF progress andprognosis. EDF manifests in different forms in multiple pathologies, buttherapeutics aimed at remedying altered H2S bioavailability maybenefit all.

AB - Endothelial dysfunction (EDF) reflects pathophysiologicalchanges in the phenotype and functions of endothelial cells that result fromand/or contribute to a plethora of cardiovascular diseases. We review the roleof hydrogen sulfide (H2S) in the pathogenesis of EDF, one of thefastest advancing research topics. Conventionally treated as an environmentpollutant, H2S is also produced in endothelial cells and participatesin the fine regulation of endothelial integrity and functions. Disturbed H2Sbioavailability has been suggested to be a novel indicator of EDF progress andprognosis. EDF manifests in different forms in multiple pathologies, buttherapeutics aimed at remedying altered H2S bioavailability maybenefit all.

KW - cystathionine gamma-lyase

KW - endothelium-derived hyperpolarizing factor

KW - gasotransmitters

KW - heme oxygenase-1

KW - hydrogen sulfide

KW - nitric oxide

UR - https://www.scopus.com/pages/publications/84941317443

U2 - 10.1016/j.tips.2015.05.007

DO - 10.1016/j.tips.2015.05.007

M3 - Article

AN - SCOPUS:84941317443

SN - 0165-6147

VL - 36

SP - 568

EP - 578

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 9

ER -